Payment overview · 2025
General Payments
$1,100.08
45 reported records · 17 companies
Healthcare provider profile · identity verified
Dmitriy V Kolesnik, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · REGO PARK, NY · NPI 1851326367
Verified facts
What the public records show
CMS Open Payments records show Dmitriy V Kolesnik, MD received $1,100.08 in general payments during 2025 across 45 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $203.91 | 18.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.08 | 13.2% | 8 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $133.07 | 12.1% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $81.60 | 7.4% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $79.46 | 7.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.21 | 6.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $74.65 | 6.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.91 | 4.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.52 | 3.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.26 | 3.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.14 | 3.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.21 | 2.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $26.90 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.99 | 2.4% | 1 | 2025 |
| Noctrix Health, Inc. | Unresolved — no canonical attribution shown | $25.61 | 2.3% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $18.04 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.52 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $941.84 | 43 |
| Consulting Fee | $150.00 | 1 |
| Education | $8.24 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $169.91 | 2 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $133.07 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.38 | 6 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $92.69 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $81.60 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $79.46 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.21 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.21 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.21 | 4 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $47.91 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $38.14 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.70 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $26.90 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| NIDRA Normalized: nidra |
Device | Noctrix Health, Inc. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 187 | 31 |
| Lamotrigine | Lamotrigine | 109 | 18 |
| Memantine Hcl | Memantine Hcl | 104 | 20 |
| Doxepin Hcl | Doxepin Hcl | 95 | 44 |
| Divalproex Sodium Er | Divalproex Sodium | 90 | 12 |
| Topiramate | Topiramate | 75 | 12 |
| Donepezil Hcl | Donepezil Hcl | 72 | 16 |
| Meloxicam | Meloxicam | 66 | 41 |
| Gabapentin | Gabapentin | 62 | 22 |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 21 |
| Baclofen | Baclofen | 50 | 18 |
| Memantine Hcl Er | Memantine Hcl | 41 | suppressed |
| Lacosamide | Lacosamide | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Briviact | Brivaracetam | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 15 |
| Xcopri | Cenobamate | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | 13 |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Botox | Onabotulinumtoxina | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Lamictal | Lamotrigine | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,100.08 · 45 records | JAZZ PHARMACEUTICALS INC. | CAPLYTA, ELYXYB - CELECOXIB, EPIDIOLEX, FANAPT, Fintepla, INFINITY, LEQEMBI, NIDRA, NURTEC ODT, QULIPTA, QUTENZA, REXULTI, Symbravo, UBRELVY, UPLIZNA, VRAYLAR, VYEPTI, WAKIX, XYREM, XYWAV, ZAVZPRET, ZTLido | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error